CAR-T Programs in Oncology

Our oncology pipeline focuses on B-cell malignancies, leveraging advanced chimeric antigen receptor (CAR) designs to selectively target and eradicate cancerous B cells. GenCART’s leading therapeutic candidates include:

• CD19 CAR-T – targeting the well-established B-cell antigen CD19, highly expressed in aggressive lymphomas and leukemias.
• CD22 CAR-T – directed against CD22, a complementary target enabling treatment of tumors that escape CD19-directed therapies.
• Dual CD19/CD22 CAR-T – an innovative construct that simultaneously targets both CD19 and CD22, aiming to reduce relapse rates and improve long-term remission.

These therapies are being developed for multiple indications, including:

• Large B-Cell Lymphoma (LBCL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Chronic Lymphocytic Leukemia (CLL)

Through this targeted approach, GenCART’s goal is to deliver durable responses while minimizing treatment-related toxicities and costs.